Key Points
- Insider purchase: David Wambeke bought 33,333 NeuroOne shares at $2.01 each, increasing his stake by 20% to 199,999 shares.
- Weak financial results: The company reported a quarterly loss of $0.28 per share, missing estimates by $0.07, while revenue of $1.97 million also fell short of expectations.
- Mixed outlook: Analysts’ consensus rating is “Hold,” with a $7.33 price target, while NMTC recently traded at $1.69 and has a 52-week range of $1.42 to $6.96.
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC - Get Free Report) insider David Wambeke purchased 33,333 shares of the stock in a transaction dated Thursday, August 27th. The stock was acquired at an average cost of $2.01 per share, with a total value of $66,999.33. Following the transaction, the insider directly owned 199,999 shares in the company, valued at approximately $401,997.99. This trade represents a 20.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
NeuroOne Medical Technologies Stock Performance
NASDAQ NMTC opened at $1.69 on Wednesday. The company has a market cap of $15.40 million, a PE ratio of -1.78 and a beta of 0.65. The firm's 50 day moving average price is $2.06 and its 200-day moving average price is $3.42. NeuroOne Medical Technologies Corporation has a 52-week low of $1.42 and a 52-week high of $6.96.
NeuroOne Medical Technologies (NASDAQ:NMTC - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.07). The company had revenue of $1.97 million for the quarter, compared to analysts' expectations of $2.17 million. NeuroOne Medical Technologies had a negative return on equity of 128.12% and a negative net margin of 71.50%. On average, analysts forecast that NeuroOne Medical Technologies Corporation will post -0.39 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of brokerages recently weighed in on NMTC. Maxim Group set a $5.00 price objective on NeuroOne Medical Technologies and gave the company a "buy" rating in a research report on Friday, August 14th. Weiss Ratings downgraded shares of NeuroOne Medical Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, August 21st. Finally, LADENBURG THALM/SH SH increased their target price on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, May 13th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $7.33.
Read Our Latest Stock Report on NeuroOne Medical Technologies
Institutional Trading of NeuroOne Medical Technologies
Large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. acquired a new position in NeuroOne Medical Technologies during the 1st quarter valued at approximately $84,000. XTX Topco Ltd acquired a new stake in shares of NeuroOne Medical Technologies during the second quarter worth $51,000. Vanguard Group Inc. grew its holdings in shares of NeuroOne Medical Technologies by 31.2% during the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company's stock valued at $1,403,000 after buying an additional 375,639 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of NeuroOne Medical Technologies in the 3rd quarter valued at $88,000. Finally, Susquehanna International Group LLP acquired a new position in shares of NeuroOne Medical Technologies in the 3rd quarter valued at $47,000. Hedge funds and other institutional investors own 16.07% of the company's stock.
NeuroOne Medical Technologies Company Profile
(
Get Free Report)
NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.
The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
